Lauren Byers
Overview
Explore the profile of Lauren Byers including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
394
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Goree J, Payakachat N, Byers L, Smith G, Shah J, Stephens K
Reg Anesth Pain Med
. 2024 Feb;
49(11):793-799.
PMID: 38388016
Introduction: Significant interindividual variability in spinal cord stimulation (SCS) outcomes exists. Due to its high cost and risks of complications, criteria to guide patient selection for SCS trials and their...
2.
Rimner A, Lai W, Califano R, Jabbour S, Rudin C, Faivre-Finn C, et al.
Clin Lung Cancer
. 2022 May;
23(5):e325-e329.
PMID: 35613997
Background: The current standard of care for patients with newly diagnosed limited-stage small-cell lung cancer (SCLC) is concurrent chemoradiotherapy (CCRT). The prognosis remains poor due to the aggressiveness and high...
3.
Della Corte C, Fasano M, Ciaramella V, Cimmino F, Cardnell R, Gay C, et al.
J Exp Clin Cancer Res
. 2022 Mar;
41(1):109.
PMID: 35346313
Background: We recently conducted Cetuximab-AVElumab-Lung (CAVE-Lung), a proof-of-concept, translational and clinical trial, to evaluate the combination of two IgG1 monoclonal antibodies (mAb): avelumab, an anti-PD-L1 drug, and cetuximab, an anti-epidermal...
4.
Tsao A, Wistuba I, Xia D, Byers L, Diao L, Wang J, et al.
JCO Precis Oncol
. 2022 Feb;
1:1-10.
PMID: 35172522
No abstract available.
5.
Goree J, Srinivasan N, Cucciare M, Zaller N, Byers L, Boateng B, et al.
J Pain Res
. 2021 Sep;
14:2583-2592.
PMID: 34466026
Objective: The aim of this study was to evaluate whether a video-based, patient-focused opioid education tool delivered in the perioperative period would decrease acute and chronic post-operative opioid prescription dispensations...
6.
Zhang B, Birer S, Dvorkin M, Shruti J, Byers L
Am Soc Clin Oncol Educ Book
. 2021 May;
41:1-10.
PMID: 33979194
Small cell lung cancer (SCLC) is an aggressive form of lung cancer with a 5-year survival rate of less than 7%. In contrast to non-small cell lung cancer, SCLC has...
7.
Carroll M, Ramalingam P, Salvo G, Fujimoto J, Solis Soto L, Phoolcharoen N, et al.
Int J Gynecol Cancer
. 2020 Jul;
30(9):1303-1307.
PMID: 32727929
Objectives: Women with recurrent high-grade neuroendocrine cervical cancer have few effective treatment options. The aim of this study was to identify potential therapeutic targets for women with this disease. Methods:...
8.
Owonikoko T, Niu H, Nackaerts K, Csoszi T, Ostoros G, Mark Z, et al.
J Thorac Oncol
. 2019 Oct;
15(2):274-287.
PMID: 31655296
Introduction: We assessed the Aurora A kinase inhibitor, alisertib, plus paclitaxel (henceforth referred to as alisertib/paclitaxel) as second-line treatment for SCLC. Methods: In this double-blind study, patients with relapsed or...
9.
Welsh J, Heymach J, Chen D, Verma V, Cushman T, Hess K, et al.
J Thorac Oncol
. 2019 Oct;
15(2):266-273.
PMID: 31605794
Intruduction: Radiation and immunotherapy have separately been shown to confer survival advantages to patients with extensive-stage small cell lung cancer (ESCLC), but failure rates remain high and combination therapy has...
10.
Nong J, Gong Y, Guan Y, Yi X, Yi Y, Chang L, et al.
Nat Commun
. 2019 Jan;
10(1):552.
PMID: 30696827
The original version of this Article contained an error in Fig. 2, in which the left y-axis labels 'tDNA' and 'ctDNA' were inadvertently inverted. This has been corrected in the...